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REVIEW ARTICLE
Magnesium: Effect on ocular health as a calcium channel antagonist
Magnezyum: Kalsiyum kanal antagonisti olarak göz sağlığı üzerindeki etkileri
Şafak Korkmaz1, Feyzahan Ekici2, Hasan Ali Tufan3, Bahri Aydın4
ÖZET
Magnezyum hücre zar fonksiyonlarını, düz kas kontrak-
siyonlarını  ve  enzimatik  reaksiyonları  etkileyerek  pek 
çok metabolik sürece katılan fizyolojik bir kalsiyum kanal 
blokörüdür. Magnezyumun Endothelin-1 (ET-1) ve Nitrik 
Oksit  (NO)  yolakları  vasıtasıyla  endotel  fonksiyonları-
nı modifiye ederek dokulara kan akımında artışa neden 
olduğu gösterilmiştir. Magnezyum aynı zamanda N-me-
til-D-aspartat (NMDA) reseptör ilişkili kalsiyum içe akımı-
nı bloke ederek ve glutamat serbestleşmesini önleyerek 
nöroprotektif rol oynamakta ve hücreleri oksidatif stres ve 
apoptoza karşı korumaktadır. Hem kan akımında artışa 
neden olması hem de nöroprotektif etkileri magnezyumu 
glokom çalışmaları için iyi bir hedef molekül yapmaktadır. 
Magnezyumun retinada oksidatif stresi ve apoptozu azalt-
tığı ve ganglion koruyucu etkileri olduğu gösterilmiştir. Bir 
takım çalışmalarda aynı zamanda magnezyumun diabe-
tik hastalarda insulin resistansını azalttığı, glisemik kont-
rolü kolaylaştırdığı ve retinopatiyi önlediği gösterilmiştir. 
Magnezyumun lensteki iyon dengesinin sağlanmasında 
kritik önemi belirlenmiştir. Magnezyum eksikliğinin lenti-
küler oksidatif stresi arttırdığı ve iyon dengesini bozarak 
katarakt oluşumuna neden olduğu gösterilmiştir.
Anahtar kelimeler: Magnezyum, kalsiyum kanal blokajı, 
glokom, nöroproteksiyon, diabetik retinopati, katarakt
ABSTRACT
Magnesium is the physiologic calcium channel blocker, 
involving in many different metabolic processes by main-
taining cell membrane function, modulating smooth mus-
cle contraction and influencing enzymatic activities. Mag-
nesium has been shown to increase blood flow to tissues 
by modifying endothelial function via endothelin-1 (ET-1) 
and nitric Oxide (NO) pathways. Magnesium also exhib-
its neuroprotective role by blocking N-methyl-D-aspartate 
(NMDA) receptor related calcium influx and by inhibiting 
the release of glutamate, hence protects the cell against 
oxidative stress and apoptosis. Both increase in blood 
flow and its neuroprotective effect make magnesium a 
good  candidate  for  glaucoma  studies.  Magnesium  has 
been shown to decrease oxidative stress and apoptosis 
in retinal tissue and to have retinal ganglion cell spar-
ing effect. A series of studies has been conducted about 
magnesium could decrease insulin resistance in diabetic 
patients, ease glycemia control and prevent diabetic reti-
nopathy. Magnesium is found to be critically important in 
maintaining normal ionic homeostasis of lens. Magnesium 
deficiency has been shown to cause increased lenticular 
oxidative stress and ionic imbalance in the lens so trigger 
cataractogenesis. J Clin Exp Invest 2013; 4 (2): 244-251
Key words:  Magnesium,  calcium  channel  blockage, 
glaucoma, neuroprotection, diabetic retinopathy, cataract
INTRODUCTION
Magnesium is an essential trace element for human 
life, and is also the second most common cation in 
the intracellular space. It plays a key role to function 
for many enzymes as a cofactor, including kinases. 
Magnesium is related to the stability of cell walls, 
and many magnesium containing enzymes are in-
volved in metabolic processes. So that magnesium 
is required for carbohydrate, protein and fat metab-
olism, maintenance of normal cell membrane func-
tion, synthesis of nucleic acid, and maintenance of 
energy metabolism [1-3].
Magnesium is a nature’s calcium blocker [4,5]. 
In addition to direct action on calcium blockage of 
vascular smooth muscle, magnesium affects endo-
thelial functions which have an impact on vascular 
tone and blood flow regulation. Magnesium reduces 
vascular tone and increases blood flow by modu-
lating production of vasoactive agents such as en-
dothelin-1 (ET-1) and nitric oxide (NO) and respon-Korkmaz et al. Effect of magnesium on ocular health 245
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siveness to these agents [6]. Elevated magnesium 
levels prevents ET-1 induced contractile responses 
by inhibition of ET-1’s production and its hypertro-
phic effect [7,8]. Endothelium-dependent vasodila-
tion mediated by NO is induced with magnesium 
by modifying formation and release of NO [9-11]. 
Indeed,  magnesium  therapy  may  improve  endo-
thelial function in patients with diabetes and coro-
nary artery diseases [12,13]. Magnesium tends to 
increase blood flow, and decreases vascular resis-
tance in various vascular beds [6,9,12,14]. Hence 
magnesium has been shown to inhibit vasospasm 
in subarachnoid hemorrhages [15] and also induces 
vasodilation in pre-eclampsia clinically [16].
Magnesium  has  gained  attention  as  an  ac-
cepted  neuroprotective  agent.  Glutamate  is  the 
major excitatory neurotransmitter in the vertebrate 
central nervous system. Excessive exposure with 
by glutamate may destroy neuronal tissue, through 
N-methyl-D-aspartate (NMDA)-mediated excitotox-
icity  [17,18].  Glutamate  induces  accumulation  of 
excessive intraneuronal calcium via overactivation 
of NMDA receptors, and thus leads to apoptotic cell 
death as a result of increased production of intra-
cellular reactive oxygen species [19,20]. Glutamate 
excitotoxicity is thought to be involved in the dura-
tion times of various number of neuronal diseases 
including  ischemic  and  traumatic  brain  injury, Al-
zheimer and Parkinson’s disease, and glaucoma by 
changing their form from acute to chronic [21,22]. 
Magnesium may prevent glutamate induced neuro-
toxicity by blocking NMDA receptor related calcium 
influx  and  by  inhibiting  the  release  of  glutamate, 
hence magnesium protect the cell against oxidative 
stress and apoptosis [23-25]. Indeed, other poten-
tial neuroprotective mechanism attributed for mag-
nesium is considered to be increasing blood flow 
dependent of vasodilator effect on calcium channel 
blockade [15,26,27].
Necessity in terms of eye tissue development
Very little is known about ocular diseases related 
to  magnesium  deprivation  in  clinical  practice.  A 
number of experimental animal studies have shown 
that magnesium has a vital role in development and 
function  of  eye.  Magnesium  deficiency  has  been 
correlated  with  multifocal  necrosis  in  retinal  pig-
ment epithelium as well as photoreceptor outer seg-
ment deformation and pyknotic-apoptotic changes 
in  photoreceptor  cell  nuclei,  probably  as  a  result 
of magnesium and calcium distribution imbalance 
in retinal tissue [28]. Magnesium may protect the 
cells against the effects of glutamate, peroxynitrite, 
oxygen radicals and the other pathways of calcium 
related excitotoxicity. Magnesium influences super-
oxide dismutase activity in retinal tissue [29]. Mag-
nesium is required for enzyme activity and mem-
bran integrity in retinal tissue as well as all human 
tissues. Magnesium is involved in all kinase reac-
tions. It means that almost all enzymatic reactions 
that involve adenosine triphosphate (ATP) definitely 
require  magnesium.  Both  disturbed  metabolism 
and antioxidation pathway may contribute to mag-
nesium deficiency induced retinal damage. Hypo-
magnesemia has been associated with pigmentary 
retinal degenerations like Kearns-Sayre syndrome 
and retinitis pigmentosa [30,31]. Interestingly, visual 
field progression has been stabilized after magne-
sium replacement in retinitis pigmentosa [31]. Mag-
nesium also exists at high concentrations in retinal 
photoreceptors and has some physiologic activity 
on vision [32-34]. Caddell proposed a hypothesis 
that magnesium deficiency may be one of causative 
factors for the pathogenesis of retinopathy of pre-
maturity as well as high arterial oxygen pressure, 
because  magnesium  deficiency  results  in  impair-
ment  of  both  vasodilatator  activity  and  protection 
from oxidative injury [35]. Magnesium deprivation 
during developmental phase may cause myelina-
tion disorders and multifocal necrosis in optic nerve 
[36]. Magnesium also may be necessary for mainte-
nance of corneal surface health which is important 
for protection from infections and dryness. Cornea 
has showed some structural changes if magnesium 
is  missing  in  the  developmental  cycle,  including 
decreased microvilli in the epithelial cells, nuclear 
changes like apoptosis in the epithelial and endo-
thelial cells through abnormal ATP activity and ab-
normal ion transport [37].
Putative therapeutic effect in glaucoma
Glaucoma  is  characterized  by  progressive  retinal 
ganglion  cell  loss  with  a  complex  pathogenesis. 
Intraocular pressure (IOP) is considered the main 
risk  factor  of  glaucoma,  and  IOP  lowering  thera-
pies plays essential role in glaucoma progression 
control.  However,  glaucomatous  damage  may 
proceed progressively despite keeping IOP at the 
level of low teens [38], and also there is a concept 
of normal tension glaucoma (NTG) with IOP that 
is  consistently  at  or  below  21  mmHg,  as  known. 
Accordingly, the factors other than IOP may con-
tribute to pathogenetic mechanism at least sensi-
tizing  the  ganglion  cell  for  IOP-induced  damage. 
Vascular dysregulation deserves attention for this 
issue. Vascular dysregulation is caused by imbal-
ance between vasoconstriction and vasodilatation 
at microcirculatory level. Vascular dysregulation in-
duces perfusion instability, and then leads to isch-Korkmaz et al. Effect of magnesium on ocular health 246
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emia, reperfusion injury and oxidative stress. Local 
disturbed autoregulation in ocular tissues is thought 
to be as a part of primary vascular dysregulation 
syndrome which is caused by general dysfunction 
of endothelium and autonomic nervous system as 
seen in whole body [39-42]. Vascular tone is reg-
ulated  locally  by  endothelium  derived  vasoactive 
agents such as ET-1 and NO. A number of studies 
have demonstrated the increased plasma ET-1 lev-
els in glaucoma patients, which could contribute to 
glaucoma pathogenesis particularly in NTG [43-45]. 
Indeed, increased ET-1 level was associated with 
glaucoma  progression  despite  normal  IOP  level 
[46]. ET-1 induces contraction of retinal and optic 
nerve head vessels, which is dependent on an in-
flux of extracellular calcium through voltage-gated 
calcium channels, and then resulting in decreased 
ocular blood flow and ischemia [47-52]. Efficacy of 
ET-1 can be inhibited by calcium channel blockade. 
So that calcium channel blockers were evaluated for 
the management of glaucoma. In this sense, some 
calcium  channel  blockers  have  shown  a  positive 
effect on ocular blood flow and visual field in NTG 
[50,53,54]. But many systemic side effects such as 
hypotension, bradycardia, conduction disturbances 
and decrease in cardiac output can be seen during 
the calcium channel blocker intake, resulting in a 
restriction in the use for chronic diseases such as 
NTG [55].
Magnesium acts as a natural physiologic cal-
cium  antagonist  with  minimal  side  effects.  Mag-
nesium-induced  favorable  vascular  effects  have 
been  demonstrated  in  many  organ  systems  and 
previously  discussed  [12,13,26]. Therefore,  these 
could  explain  how  magnesium  may  have  poten-
tial therapeutic effect in some diseases associated 
with  perfusion  abnormality  via  local  microcircula-
tory disturbances and decreased blood flow such 
as NTG. Gaspar et al. [56] evaluated the effect of 
oral magnesium therapy in 10 glaucoma patients 
(6 with open angle glaucoma and 4 with NTG with 
normal or drug normalized IOP). All patients had a 
cold-induced digital vasospasm. 121.5 mg of mag-
nesium was given twice daily for 1 month and vid-
eo-nailfold-capillaroscopy was used to evaluate pe-
ripheral capillary blood flow. At the end of 4 weeks 
of treatment, both peripheral blood flow and visual 
field were improved, as the former was statistically 
significant and the latter not. They concluded that 
magnesium seemed to have a beneficial effect on 
the visual field in glaucoma patients [56]. Similarly, 
Aydın  et  al.  [57]  investigated  the  efficacy  of  oral 
magnesium supplementation on visual field perim-
etry indices and ocular blood flow in pure NTG by 
a  prospective  controlled  randomized  clinical  trial. 
Fifteen NTG patients were received 300 mg oral 
magnesium for 1 month and blood flow velocity of 
orbital vessels such as ophthalmic, posterior ciliary 
and central retinal arteries were measured by color 
Doppler imaging. After 1 month of magnesium ther-
apy, the improvement in visual field mean deviation 
and pattern standard deviation were found statisti-
cally significant in the study group compared with 
control group. They did not report any significant 
change in ocular blood flow parameters provided 
by color Doppler imaging. Authors speculated that 
other mechanisms than increased blood flow could 
be  responsible  for  the  improvement  in  the  visual 
field [57].
The known facts about impact of magnesium 
on the ocular blood flow are limited. Elevated ex-
tracellular concentrations of magnesium inhibit ET-
1-induced  contraction  in  porcine  ciliary  arteries. 
However,  complete  inhibition  was  achieved  only 
with very high concentrations of magnesium, suffi-
cient to provoke cardiac arrest [58]. Magnesium in-
fluences vascular tonus in dose-dependent manner 
via calcium antagonistic effect non-competitively. It 
was shown that non-toxic lower dose could be quite 
enough for visual improvement in NTG, higher con-
centrations may not be needed. The 300 mg/day 
oral magnesium intake may have an effect on more 
distal vasculature (particularly the capillaries) which 
cannot be revealed by color Doppler analysis [57]. 
More likely, the perfusion anomaly caused by vas-
cular dysregulation at microcirculatory level is regu-
lated by magnesium without the need of increased 
blood flow of orbital vessels, in a mechanism which 
possibly related to calcium antagonistic effect. This 
impact can be explained by regulation of endothelial 
function by magnesium. Magnesium therapy may 
also improve endothelial function [12,13]. In addi-
tion  to  reverse  interaction  with  ET-1,  magnesium 
induces  endothelium-dependent  vasodilation  me-
diated by endothelial NO [9,10]. NO, derived from 
nitric  oxide  synthase-3  in  vascular  endothelium, 
contributes to regulation of local circulatory distur-
bances, and may be neuroprotective by causing va-
sodilation and increased blood flow in the glaucoma 
patients [59,60].
Repeated reperfusion injury which occurs as a 
result of perfusion instability via vascular dysregu-
lation induces glutamate retention in retinal tissue. 
Glutamate is the principal excitatory neurotransmit-
ter in retina as discussed before [61]. Elevated glu-
tamate has been demonstrated in vitreous of glau-
coma patients [21]. Exposure to chronic low dose 
glutamate could damage retinal ganglion cells [18]. Korkmaz et al. Effect of magnesium on ocular health 247
J Clin Exp Invest   www.jceionline.org   Vol 4, No 2, June 2013
Glutamate induced excitotoxicity is predominantly 
managed by NMDA subtype of glutamate receptor.
Overstimulation  of  NMDA  receptors  leads  to 
excessive calcium influx through NMDA receptors 
and  voltage-gated  calcium  channels,  and  then  a 
number  of  enzymes  become  inappropriately  acti-
vated to promote apoptotic cell death [19]. Calcium 
influx into retinal ganglion cells through NMDA re-
ceptors  seems  to  have  major  value  in  producing 
permanent damage, and may be a critical step that 
can be interfered. NMDA receptor antagonists such 
as  memantine  and  MK-801  and  dihydropyridine 
derived  calcium  channel  antagonists  have  been 
shown to attenuate NMDA related neurotoxicity in 
retinal  ganglion  cells  [17,18,62]. As  a  physiologi-
cal calcium channel blocker, magnesium may be a 
good alternative in terms of neuroprotection of reti-
nal ganglion cells with minimal side effects. Magne-
sium ions proceed to regulate conductance of the 
NMDA channels by blocking the pores in a voltage 
dependent manner, and to limit neuronal calcium 
influx [63]. Elevated magnesium levels can also in-
hibit influx of calcium non-competitively at NMDA 
receptors [64,65]. Calcium mediated neurotoxicity 
depends on the activation of distinct signaling path-
ways resulting in free radical generation, which is 
also triggered by NMDA receptor. Magnesium de-
ficiency may promote oxidative injury. Magnesium 
can  prevent  retinal  ganglion  cells  from  oxidative 
injury by combined effects on NMDA receptor ac-
tivity,  glutathione  synthesis  and  lipid  peroxidation 
[66,67]. Magnesium also influences superoxide dis-
mutase activity in retinal tissue [19]. Magnesium is 
required for glutathione biosynthesis and its deple-
tion has been associated with decreased antioxi-
dant properties [68,69]. Oxidative stress is involved 
in glaucoma pathogenesis [70]. Overproduction of 
NO by neuronal and inducible NO synthesis acts 
as neurodestructive agent because of the produc-
tion of peroxynitrites [59]. Reduced oxidative load 
intervened by magnesium may also contribute to at-
tenuate progression of glaucoma. 
In  conclusion,  some  evidence  supports  that 
magnesium can prevent the loss of neuron in glau-
coma via an undefined mechanism. Only two stud-
ies have shown meritorious effect of magnesium on 
visual fields clinically. Further studies are required 
to confirm these findings, and to reveal the underly-
ing pathways.
Association of diabetic retinopathy
Clinical  and experimental  evidences  suggest that 
magnesium may reduce the risk of diabetic retinop-
athy in patients with diabetes. Magnesium may play 
an  important  role  in  the  maintenance  of  glucose 
metabolism and insulin homeostasis. Dietary mag-
nesium  intake  and  serum  magnesium  level  have 
been inversely correlated with fasting serum insulin 
level and positively correlated with markers of insu-
lin sensitivity [71,72]. A graded inverse relationship 
between serum magnesium level and incidence of 
type 2 diabetes has been shown prospectively by 
the Atherosclerosis Risk in Communities Study, and 
low serum magnesium levels were found to be an 
independent predictive factor for the incidence of di-
abetes [73]. Further studies tended to confirm simi-
lar association so that plasma magnesium concen-
tration in diabetic patients is lower than non-diabetic 
patients [74-77]. The mechanisms of how magne-
sium could affect insulin resistance or reduce dia-
betic complications like diabetic retinopathy are not 
defined yet. Magnesium acts as a natural calcium 
antagonist [4]. Elevated cytosolic free calcium con-
centration causes the deficiency of insulin actions 
on glucose uptake, and leads to worsen hypergly-
cemia [78,79]. Magnesium may regulate insulin ac-
tions through interfering the effect of calcium. Oth-
erwise many enzymes of carbohydrate metabolism 
require magnesium as a cofactor [80]. Low intracel-
lular magnesium concentrations result in a defective 
tyrosine-kinase activity and alter insulin sensitivity 
by  disrupting  signaling  pathway  interaction  at  re-
ceptorial or postreceptorial phase [81-84]. It is also 
likely that magnesium can improve insulin actions 
through altering directly enzyme function involving 
in  glucose  matabolism.  Hyperglycemia  may  get 
worse because of low magnesium-induced insulin 
resistance. All these evidences suggest that mag-
nesium may have effect on pathogenesis and treat-
ment  of  diabetic  retinopathy.  Plasma  magnesium 
concentration of diabetic patients with retinopathy 
has been shown to tend to be lower when compared 
with diabetic patients without retinopathy [76,77,85-
87]. Hypomagnesemia has also been linked to the 
most severe degree of retinopathy [76,85,87]. One 
prospective  study  demonstrated  an  inverse  rela-
tionship  between  plasma  magnesium  level  and 
both development and progression of diabetic reti-
nopathy at the end of long term follow up. A similar 
relationship remained unchanged after adjusting for 
the potential confounding effects of hemoglobinA1c 
and disease duration [87]. In contrast to these ob-
servations, some studies have not found similar as-
sociation, and supported that there was no consis-
tent association between serum level of magnesium 
and diabetic retinopathy [88-90]. Lastly, conflicting 
reports can be seen on this issue. In terms of de-
velopment and progression of diabetic retinopathy, 
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indicator or a causative factor has not been yet un-
derstood.  Although  magnesium  probably  plays  a 
role to break down insulin resistance in peripheral 
target tissues, to what extent this influence might be 
effective for preventing retinopathy is a matter of de-
bate. Magnesium may be protector against diabetic 
retinopathy, but it is clear that further evaluation is 
needed to reveal true etiologic association between 
magnesium and diabetic retinopathy if there is.
Magnesium: Have a role in cataractogenesis?
Magnesium, a common cation that plays an impor-
tant role as a cofactor for numerous enzymes, is 
closely linked with calcium, sodium and potassium 
homeostasis. The integrity of lens both structurally 
and  functionally  largely  depends  on  the  mainte-
nance of intracellular and extracellular ionic homeo-
stasis. Magnesium is found to be critically important 
in  maintaining  normal  ionic  homeostasis  of  lens. 
Two main enzymes, sodium potassium adenosine 
triphosphatase (Na+ K+ ATPase) and calcium ade-
nosine triphosphatase (Ca2+ ATPase), which seem 
very important to lens active ion transport mecha-
nism use magnesium as a cofactor and are largely 
magnesium dependent [91]. 
Role of magnesium in the onset and progres-
sion of cataract has been evaluated by various re-
searchers. It was found that the ionic imbalance in 
age related cataract is mainly associated with de-
creased magnesium and potassium and increased 
calcium and sodium [92]. Also magnesium supple-
mentation has been shown to have a preventive role 
in Shumiya cataract rats [93]. It is clearly indicated 
that magnesium deficiency is correlated with high 
calcium levels in the lens. Probably the oxidative 
stress  resulting  from  magnesium  deficiency  play 
a role to increase lens calcium concentration and 
finally result in cataractogenesis [94]. Magnesium 
deficiency  has  been  shown  to  cause  increased 
oxidative stress and trigger cataractogenesis by in-
creasing inducible NO synthase (iNOS) expression 
and NO release. Pretreatment of rats with NO syn-
thase inhibitors has been shown to prevent onset of 
selenite-induced cataract and reduce lens calcium 
content [95]. Culture of human lens epithelial cells in 
magnesium deficient medium shows 6 fold increase 
in expression of İNOS as compared to those cul-
tured in medium with normal magnesium concen-
tration. Also treatment of culture medium with İNOS 
inhibitors attenuate increased release of NO [96]. 
In another study it was shown that treatment with 
magnesium taurate also delays the onset and pro-
gression of cataract in galactose fed rats. This effect 
was attributed to the restorage of the lens calcium/ 
magnesium ratio and the reduction of the lenticular 
oxidative stress [97].
Magnesium deficiency causes increased len-
ticular  oxidative  stress,  alterations  in  function  of 
ATPases  resulting  in  ionic  imbalances  consist  of 
reduced intracellular potassium and increased cal-
cium and sodium levels. Increased sodium causes 
cellular swelling and increased calcium causes con-
vertion of soluble proteins into insoluble ones. All 
these changes finally result in cataractogenesis. Al-
though current literature provides evidence for the 
association of magnesium deficiency with cataract, 
its role can be thought as an associated factor with 
several other factors.
CONCLUSION
Magnesium is of critical importance in regulating in-
tracellular enzymatic functions including those of oc-
ular tissue. The role of magnesium in several ocular 
diseases has been studied widely. The association 
of magnesium levels with ocular pathologies such 
as glaucoma, diabetic retinopathy and cataract may 
primarily attributed to its highly important role as a 
cofactor for membrane associated ATPases, vessel 
smooth muscle modulating effects and also role in 
oxidative stress regulation mechanisms. The review 
of current literature supports the need of further in-
vestigations to evaluate the role of magnesium as 
a supportive approach in various ocular diseases.
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